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Theincreasing administrative burden associated with conducting clinical trials is a threatto patient safety, independent academic clinical research, and access to affordableinnovation. While the Clinical Trials Regulation1—adopted by the EuropeanParliament in 2014 to replace the Clinical Trials Directive2 (from 2001) and finally
expected to become applicable in the course of 2020—will go some way in addressing bureaucracy
overload, more action is needed. This article discusses the issues resulting from the exponential
growth of regulatory and administrative requirements for the conduct of clinical studies and the
impact this is having on researchers and patients. It also describes how the European Hematology
Association (EHA) is coordinating a series of activities to advance potential solutions for these
issues.
Issues of safety reporting
Nothing is more important than the safety of our patients in clinical trials and there is a need to
communicate new and important safety data to investigators. However, researchers now receive a
significant amount of information on (1) side effects that are already well known, (2) side effects
alleged to be treatment-related that are not, or (3) suspected unexpected serious adverse reactions
(SUSARs) that are revealed to be neither unexpected nor serious.3 This large and uncontrolled
volume of information is now diluting and masking the truly important SUSAR reports, thereby
compromising patient safety. It is evident that this issue is due, in part, to the overinterpretation of
regulations by Contract Research Organizations (CROs),4,5 which require even minor events to be
documented and reported to fulfill the frequent audits and inspections to which they are
subjected.6 A simplified and less ambiguous formulation of the laws would help to prevent the
overinterpretation of legislation. However, it is important to stress that physicians should not be
encouraged to under-report serious adverse events (SAEs), as seemingly minor events could be
significant if they occur in large numbers of patients.
Another issue with regard to safety reporting during clinical trials is that reported adverse events
(AEs) tend to reflect investigators’ impressions of these events rather than actual patient
experience.7,8 The methods currently used for detecting AEs in clinical trials are recognized as
having limitations.9 It has been suggested that direct reporting of AEs by patients, as opposed to
relying on data recorded by clinicians or trial practitioners, could be a better approach that would
both improve the quality of safety information and allow the earlier detection of SAEs.10,11 We
envision the introduction of simplified risk adapted reports, integrating data from electronic
medical records.
We strongly recommend that regulators involve the key stakeholders—clinical researchers and
patients—in the drafting of guidance documents for safety reporting. It is promising that the latest
revision of the questions and answers document on Clinical Trials Regulation by the Directorate-
General for Health and Food Safety of the European Commission now includes a separate chapter
on safety reporting.12 Furthermore, the US Food and Drug Administration (FDA) is currently
revising its guidelines for safety reporting13 and has recently issued a related questions and answers
document.14
Informed consent forms
Several issues have been identified with the current informed consent process for participation in
clinical trials. Informed consent forms (ICFs) are often too complicated for trial participants to
understand, use complex scientific terminology, and demonstrate poor readability.15 In addition,
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they are often too long and cannot easily be translated into
multiple languages.16 As a result, many participants, especially
those from less developed countries, may not understand the
clinical trial despite having signed the ICF.15
In the USA, it is required to include a key information section
summarizing the ICF, but patients are still expected to read the
complete form.17 We suggest that the key information page in an
ICF be considered sufficient and only this page should be
mandatory, with further details available for those who are
interested. We also feel that ICFs should be critically reviewed by
patient representatives and that their opinions should carry more
weight than the opinions of lawyers, given that the document is
aimed at patients.
Another issue is that re-consent is often required during the
course of a clinical trial due to ICF amendments, but this can
cause confusion and anxiety among some participants.18 It has
been suggested that the re-signing of consent forms should only
be necessary for ethical reasons, such as to protect participants
from harm in the event of new findings about AEs, to maintain
participant autonomy, or in the case of legally defective ICFs.
Additionally, research review committees such as institutional
review boards should oversee the re-consent process to ensure
that participants are not contacted unnecessarily.18
As a starting point to simplify ICFs, EHA is developing a
European ICF template through discussion with multiple stake-
holders, including patient representatives. Another solution to
the issue could be to make clinical trial documents publicly
available to enable patients and other interested stakeholders to
provide input into the ICFs. Alternatively, ICFs could be
developed through procedures used for the drafting of other
patient-focused documents, such as package leaflets. The latter
must strictly adhere to the European Medicines Agency (EMA)
Quality Review of Documents template and official glossaries,19
and their readability is validated and continuously reviewed.20
Regulatory challenges
The administrative demands associated with current regulato-
ry processes for the conduct of clinical trials are time consuming,
at times clinically irrelevant, and partly responsible for the rising
costs of developing new drugs.3 CROs are necessary to manage
this increasing amount of administration, but their personnel are
not always experts in the area under investigation. Consequently,
researchers often receive numerous queries from CROs that are
unimportant yet involve an inordinate amount of paperwork.3 By
law, clinical trial sponsors are ultimately responsible for the
conduct of their clinical trials and, therefore, retain responsibility
for the management of any contractor, including associated
bureaucracy and any impact it may have. As a practical solution,
regulators could set a framework for the conduct of CROs to
prevent bureaucracy from spiraling out of control. If left
uncontrolled, bureaucracy and the increasing costs of conducting
clinical trials could lead to the disappearance of independent
academic clinical researchers, particularly new researchers who
may not have a supportive infrastructure to cope with these ever
increasing administrative demands.3
Another channel for addressing these two interrelated issues—
overinterpretation/over-reporting and an imbalanced relation-
ship between CROs, sponsors and investigators—is the Interna-
tional Council for Harmonization of Technical Requirements for
Pharmaceuticals for Human Use (ICH). ICH, which brings
together regulatory authorities and the pharmaceutical industry,
has released the E8 revised guideline on General Considerations
for Clinical Trials for public consultation21 and is also revising
guideline E6 on Good Clinical Practice.22We are heartened to see
that multiple stakeholders including healthcare providers,
academia, and patient organizations, are being invited to
participate in workshops organized as part of the revision
process.
Role of EHA
EHA is identifying specific issues23 and is facilitating
discussions between clinical researchers, regulators, and other
relevant stakeholders to address the issues resulting from the
increasing administrative burden associated with conducting
clinical trials. As a first step, a workshop was held at the EHA
Executive Office in The Hague on June 27, 2019, to discuss
bureaucratic obstacles in clinical research.24 This workshop was
attended by different stakeholders involved in the legislation and
conduct of clinical trials, including clinical researchers, the
European Commission, EMA, FDA, and patient organizations.
As a follow-up to this meeting, EHA is actively participating in
revisions of the ICH E8 and E6 guidelines and has provided input
to the European Commission on the latest revision of the Clinical
Trials Regulation questions and answers document.12 EHA is
also aligning with key stakeholders, including the Biomedical
Alliance in Europe, to develop specific actions. These include the
creation of a ‘conduct of clinical research’ roadmap and a
consensus opinion document on ICFs (for sharing with the
European Commission). In addition, EHA is engaging with
clinical researchers and patients outside of the hematology
community to encourage cross-disciplinary debate of the current
challenges associated with the conduct of clinical research.
Call for action
We call on regulators to ensure structural involvement of
patients and clinical researchers in the formulation of informed
consent forms and guidance documents for safety reporting and
other aspects of clinical studies. Regulators should also set a
framework for the conduct of CROs to prevent bureaucracy from
spiraling out of control.
Clearly, bureaucracy in clinical research is a challenge faced
not only by hematologists and their patients. EHA therefore calls
on medical societies and patient organizations across disciplines
to work together to develop a ‘roadmap towards patient-centric,
bureaucracy-light clinical research’ in close dialogue with
industry, policymakers, and regulators. Collectively, we must
ensure that the interests of patients and clinicians are placed back
at the center of the design and implementation of clinical trials.
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